These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 9476060)
1. Cancer of the uterine cervix: sensitivity and specificity of serum Cyfra 21.1 determinations. Callet N; Cohen-Solal Le Nir CC; Berthelot E; Pichon MF Eur J Gynaecol Oncol; 1998; 19(1):50-6. PubMed ID: 9476060 [TBL] [Abstract][Full Text] [Related]
2. Cytokeratin subunit 19 measured by CYFRA 21-1 assay in follow-up of cervical cancer. Kainz C; Sliutz G; Mustafa G; Bieglmayr C; Koelbl H; Reinthaller A; Gitsch G Gynecol Oncol; 1995 Mar; 56(3):402-5. PubMed ID: 7535720 [TBL] [Abstract][Full Text] [Related]
3. Cyfra 21-1 in monitoring cervical cancer: a comparison with tissue polypeptide antigen and squamous cell carcinoma antigen. Bonfrer JM; Gaarenstroom KN; Korse CM; Van Bunningen BN; Kenemans P Anticancer Res; 1997; 17(3C):2329-34. PubMed ID: 9245246 [TBL] [Abstract][Full Text] [Related]
4. A combination of serum tumor markers identifies high-risk patients with early-stage squamous cervical cancer. Davelaar EM; van de Lande J; von Mensdorff-Pouilly S; Blankenstein MA; Verheijen RH; Kenemans P Tumour Biol; 2008; 29(1):9-17. PubMed ID: 18497544 [TBL] [Abstract][Full Text] [Related]
5. Study of a new tumor marker, CYFRA 21-1, in squamous cell carcinoma of the cervix, and comparison with squamous cell carcinoma antigen. Tsai SC; Kao CH; Wang SJ Neoplasma; 1996; 43(1):27-9. PubMed ID: 8843956 [TBL] [Abstract][Full Text] [Related]
6. Comparison of Cyfra 21-1 and SCC assays in head and neck tumours. Banal A; Hacene K; Berthelot-Ruff E; Mahé E; Fontana X; Pichon MF Tumour Biol; 2001; 22(1):27-35. PubMed ID: 11054024 [TBL] [Abstract][Full Text] [Related]
7. Serum CYFRA 21-1 assay in squamous cell carcinoma of the cervix. Ferdeghini M; Gadducci A; Annicchiarico C; Prontera C; Malagnino G; Castellani C; Facchini V; Bianchi R Anticancer Res; 1993; 13(5C):1841-4. PubMed ID: 7505543 [TBL] [Abstract][Full Text] [Related]
8. Serum squamous cell carcinoma antigen and CYFRA 21-1 in cervical cancer treatment. Pras E; Willemse PH; Canrinus AA; de Bruijn HW; Sluiter WJ; ten Hoor KA; Aalders JG; Szabo BG; de Vries EG Int J Radiat Oncol Biol Phys; 2002 Jan; 52(1):23-32. PubMed ID: 11777619 [TBL] [Abstract][Full Text] [Related]
9. Serum CYFRA 21-1 in cervical cancer patients treated with radiation therapy. Suzuki Y; Nakano T; Ohno T; Abe A; Morita S; Tsujii H J Cancer Res Clin Oncol; 2000 Jun; 126(6):332-6. PubMed ID: 10870643 [TBL] [Abstract][Full Text] [Related]
10. Clinical value of pretreatment serum Cyfra 21-1, tissue polypeptide antigen, and squamous cell carcinoma antigen levels in patients with cervical cancer. Gaarenstroom KN; Bonfrer JM; Kenter GG; Korse CM; Hart AA; Trimbos JB; Helmerhorst TJ Cancer; 1995 Sep; 76(5):807-13. PubMed ID: 8625184 [TBL] [Abstract][Full Text] [Related]
11. Comparison of CYFRA 21-1 and squamous cell carcinoma antigen in detecting nasopharyngeal carcinoma. Lee JK; Hsieh JF; Tsai SC; Ho YJ; Sun SS; Kao CH Ann Otol Rhinol Laryngol; 2001 Aug; 110(8):775-8. PubMed ID: 11510737 [TBL] [Abstract][Full Text] [Related]
12. [Investigation of the usefulness of CYFRA 21-1 as a tumor marker in squamous cell carcinomas of the head and neck]. Sano K; Kataoka S; Katoh T; Kawauchi H; Morikawa S Nihon Jibiinkoka Gakkai Kaiho; 1997 Jul; 100(7):790-7. PubMed ID: 9277101 [TBL] [Abstract][Full Text] [Related]
13. [Usefulness of the SCC, CEA, CYFRA 21.1, and CRP markers for the diagnosis and monitoring of cervical squamous cell carcinoma]. Chmura A; Wojcieszek A; Mrochem J; Walaszek-Gruszka A; Deja R; Masłyk B; Bartnik W; Sodowski K Ginekol Pol; 2009 May; 80(5):361-6. PubMed ID: 19548456 [TBL] [Abstract][Full Text] [Related]
14. CYFRA 21.1 in patients with cervical cancer: comparison with SCC and CEA. Molina R; Filella X; Augé JM; Bosch E; Torne A; Pahisa J; Lejarcegui JA; Rovirosa A; Mellado B; Ordi J; Biete A Anticancer Res; 2005; 25(3A):1765-71. PubMed ID: 16033097 [TBL] [Abstract][Full Text] [Related]
15. Monitoring of therapy in head and neck patients during the radiotherapy by measurement of Cyfra 21-1. Pradier O; Hille A; Schmiberger H; Hess CF Cancer Radiother; 2002 Feb; 6(1):15-21. PubMed ID: 11899676 [TBL] [Abstract][Full Text] [Related]
16. Significance of elevated SCC-Ag level on tumor recurrence and patient survival in patients with squamous-cell carcinoma of uterine cervix following definitive chemoradiotherapy: a multi-institutional analysis. Choi KH; Lee SW; Yu M; Jeong S; Lee JW; Lee JH J Gynecol Oncol; 2019 Jan; 30(1):e1. PubMed ID: 30479085 [TBL] [Abstract][Full Text] [Related]
17. Diagnostic value of SCC, CEA and CYFRA 21.1 in lung cancer: a Bayesian analysis. Pastor A; Menéndez R; Cremades MJ; Pastor V; Llopis R; Aznar J Eur Respir J; 1997 Mar; 10(3):603-9. PubMed ID: 9072992 [TBL] [Abstract][Full Text] [Related]
19. The assessment of the prognostic value of tumor markers and cytokines as SCCAg, CYFRA 21.1, IL-6, VEGF and sTNF receptors in patients with squamous cell cervical cancer, particularly with early stage of the disease. Kotowicz B; Fuksiewicz M; Jonska-Gmyrek J; Bidzinski M; Kowalska M Tumour Biol; 2016 Jan; 37(1):1271-8. PubMed ID: 26289850 [TBL] [Abstract][Full Text] [Related]
20. Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA) as tumour markers in bronchogenic carcinoma. Huang MS; Jong SB; Tsai MS; Lin MS; Chong IW; Lin HC; Hwang JJ Respir Med; 1997 Mar; 91(3):135-42. PubMed ID: 9135852 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]